Ozempic’s early success in kidney disease trial drags down dialysis stocks
By Mariam ESunny (Reuters) – Shares of dialysis service providers fell sharply on Wednesday after Novo Nordisk’s Ozempic showed early signs of success in delaying the progression of kidney disease in diabetes patients. Colorado-based DaVita’s shares closed down about 17% and U.S.-listed shares of German rival Fresenius Medical ended 17.6% lower. Novo’s announcement is the …
Ozempic’s early success in kidney disease trial drags down dialysis stocks Read More »










